-
Mashup Score: 0Abrocitinib Effective for Eczema Patients with Inadequate Response to Upadacitinib, Dupilumab - 2 month(s) ago
This research also included results from a sub-analysis of non-responders with hand eczema to dupilumab and upadacitinib.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
“Discover the latest partnership between Estée Lauder’s Clinique and Mount Sinai, creating a dermatology center to research skin health and develop solutions fo
Source: www.beckershospitalreview.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6Lawrence Eichenfield, MD: On Verrica Receiving Permanent J-Code for Cantharidin Treatment of Molluscum - 2 month(s) ago
This segment of Eichenfield’s interview features a discussion about the recent announcement of a J-Code for the molluscum contagiosum treatment cantharidin.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Eingun James Song, MD: Tips, Tricks for Dermatologists Treating Palmoplantar Psoriasis - 3 month(s) ago
In this discussion with E. James Song, MD, several unique clinical pearls for those in dermatology were described and had been drawn from Song’s Winter Clinical presentation.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Deroofing, Laser Treatments Introduced for Patients in the UK with Hidradenitis Suppurativa - 3 month(s) ago
The THESEUS study was conducted to look at current HS management and the influences on treatment decisions, with the goal of informing future randomized controlled trials.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0The Cutaneous Connection - 4 month(s) ago
Listen to The Cutaneous Connection on Spotify. From the latest updates in dermatology to exclusive interviews with leading industry experts and a glimpse at what goes on behind the scenes, the staff at Dermatology Times brings you a podcast that will explore the impact of new data and support you in implementing innovative technologies that advance your patient care and practice. Join us under the dermatoscope for The Cutaneous Connection.
Source: open.spotify.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 5AAD.org Login - 4 month(s) ago
Create a non-member account if you are applying for membership or need to interact with AAD systems. Non-member accounts do not have access to the member-only sections of our
Source: identity.aad.orgCategories: General Medicine News, DermatologyTweet-
#Dermatology is comanaging with rheumatology the treatment of a 60-year-old woman with refractory systemic lupus erythematosus and severe skin manifestations involving the face, arms and trunk. Therapeutic trials with systemic and topical corticosteroids...https://t.co/iR9wxav1uB https://t.co/HZ0eySKztz
-
-
Mashup Score: 0The Cutaneous Connection - 4 month(s) ago
Listen to The Cutaneous Connection on Spotify. From the latest updates in dermatology to exclusive interviews with leading industry experts and a glimpse at what goes on behind the scenes, the staff at Dermatology Times brings you a podcast that will explore the impact of new data and support you in implementing innovative technologies that advance your patient care and practice. Join us under the dermatoscope for The Cutaneous Connection.
Source: open.spotify.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 35Thyroid Dermopathy in Graves’ Disease | NEJM - 4 month(s) ago
Images in Clinical Medicine from The New England Journal of Medicine — Thyroid Dermopathy in Graves’ Disease
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Utilizing JAK Inhibitors in Clinical Practice - 4 month(s) ago
Dermatology experts discuss the use of JAK inhibitors in clinical practice, highlighting their own experiences and use of JAKs alongside corticosteroids.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
In #dermatology news, abrocitinib was shown to be effective for atopic dermatitis patients including those with prior inadequate responses to upadacitinib or dupilumab. Want to learn more? Read our summary: https://t.co/wdGJI0NMOl